JP2024532768A - カンプトテシン誘導体、その薬物組成物およびその応用 - Google Patents

カンプトテシン誘導体、その薬物組成物およびその応用 Download PDF

Info

Publication number
JP2024532768A
JP2024532768A JP2024508407A JP2024508407A JP2024532768A JP 2024532768 A JP2024532768 A JP 2024532768A JP 2024508407 A JP2024508407 A JP 2024508407A JP 2024508407 A JP2024508407 A JP 2024508407A JP 2024532768 A JP2024532768 A JP 2024532768A
Authority
JP
Japan
Prior art keywords
group
compound
reaction solution
added
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024508407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532768A5 (https=
Inventor
ジェン リー
フォン タン
ヤーユエン フー
リーフォン リュー
チュンヤン ジャオ
レンホン タン
ジンション レン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Simcere Zaiming Pharmaceutical Co Ltd
Original Assignee
Simcere Zaiming Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simcere Zaiming Pharmaceutical Co Ltd filed Critical Simcere Zaiming Pharmaceutical Co Ltd
Publication of JP2024532768A publication Critical patent/JP2024532768A/ja
Publication of JP2024532768A5 publication Critical patent/JP2024532768A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024508407A 2021-08-19 2022-08-19 カンプトテシン誘導体、その薬物組成物およびその応用 Pending JP2024532768A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202110955364.5 2021-08-19
CN202110955364 2021-08-19
CN202111515247 2021-12-13
CN202111515247.3 2021-12-13
CN202210515797.3 2022-05-12
CN202210515797 2022-05-12
PCT/CN2022/113499 WO2023020605A1 (zh) 2021-08-19 2022-08-19 喜树碱衍生物、其药物组合物及其应用

Publications (2)

Publication Number Publication Date
JP2024532768A true JP2024532768A (ja) 2024-09-10
JP2024532768A5 JP2024532768A5 (https=) 2025-08-27

Family

ID=85239565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024508407A Pending JP2024532768A (ja) 2021-08-19 2022-08-19 カンプトテシン誘導体、その薬物組成物およびその応用

Country Status (8)

Country Link
US (1) US20250270227A1 (https=)
EP (1) EP4389752A4 (https=)
JP (1) JP2024532768A (https=)
KR (1) KR20240049583A (https=)
CN (1) CN117769555A (https=)
AU (1) AU2022330892A1 (https=)
CA (1) CA3228345A1 (https=)
WO (1) WO2023020605A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
KR20240149823A (ko) * 2023-04-06 2024-10-15 주식회사 피노바이오 항암 내성 극복을 위한 신규 캄토테신 유도체 및 이를 포함하는 항체-약물 접합체
CN120858098A (zh) * 2023-05-04 2025-10-28 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2024227439A1 (zh) * 2023-05-04 2024-11-07 四川科伦博泰生物医药股份有限公司 具有靶向作用的偶联物及其制备方法和用途
WO2025153001A1 (zh) * 2024-01-17 2025-07-24 北京泰德制药股份有限公司 含有噻唑[5,4-b]吡啶结构的抗体偶联药物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540099B1 (en) * 1991-10-29 1996-04-17 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
CN1036197C (zh) * 1992-01-28 1997-10-22 格拉克索有限公司 水溶性喜树碱衍生物
JPH1171280A (ja) * 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd 医薬組成物
BR112020020466A2 (pt) * 2018-04-06 2021-01-12 Seattle Genetics, Inc. Conjugados de peptídeo de camptotecina
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
EP4628165A3 (en) * 2021-02-05 2026-03-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof
EP4257154A4 (en) * 2021-02-09 2026-04-22 Medilink Therapeutics Suzhou Co Ltd CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE
IL308734A (en) * 2021-05-27 2024-01-01 Zymeworks Bc Inc Camptothecin analogues, conjugates and methods of use
US20240376120A1 (en) * 2021-09-01 2024-11-14 Shanghai Best-Link Bioscience, Llc Camptothecin compound, preparation method therefor and use thereof
WO2023178289A2 (en) * 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
JP2025515988A (ja) * 2022-05-13 2025-05-23 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カンプトテシン化合物、その調製方法及びその使用

Also Published As

Publication number Publication date
CA3228345A1 (en) 2023-02-23
US20250270227A1 (en) 2025-08-28
AU2022330892A1 (en) 2024-03-21
EP4389752A4 (en) 2025-08-20
CN117769555A (zh) 2024-03-26
WO2023020605A1 (zh) 2023-02-23
KR20240049583A (ko) 2024-04-16
EP4389752A1 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
JP2024532768A (ja) カンプトテシン誘導体、その薬物組成物およびその応用
CN112745335B (zh) 一种三并杂环化合物及其用途
CN115192577A (zh) Kras突变蛋白抑制剂
CN112300153B (zh) 一种杂环化合物、药物组合物和用途
CN113286796B (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
JP2025515988A (ja) カンプトテシン化合物、その調製方法及びその使用
CN112851663B (zh) 一种并杂环化合物及其用途
CA3161739A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
CN114591352B (zh) 一种三唑并哒嗪类化合物及其应用
JP2020530490A (ja) アンドロゲン受容体拮抗薬として使用されるジアリールチオヒダントイン化合物
JP2022547815A (ja) アザヘテロアリール化合物及びその使用
TW202421129A (zh) 用作 cdk4 激酶抑制劑的化合物及其應用
CN111630047B (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
JP2025539116A (ja) Ｃｄｋ２阻害剤及びその調製方法と使用
JP2025536384A (ja) ピペリジノピリミジン系誘導体、その調製方法及びその医薬的使用
CN111848629B (zh) 一类mTOR/HDAC双重抑制剂及其应用
EP4293029A1 (en) Azaheteroaryl compound, preparation method therefor, and application thereof
JP4940152B2 (ja) パモ酸オランザピン二水和物
CN117177979B (zh) 环状双苄基四氢异喹啉类化合物及其制备方法和应用
EP4647429A1 (en) Pyridazinone heterocyclic compound myosin ii inhibitor and use thereof
EP4371977A1 (en) Arylamino derivative estrogen receptor modulator and use thereof
HK40107233A (en) Camptothecin derivative, and pharmaceutical composition and use thereof
JP2025506747A (ja) イミダゾピリダジン系誘導体、その製造方法、医薬組成物及び使用
AU2017286217A1 (en) Novel dizocilpine derivatives as peripheral NMDA receptor antagonists
CN116162093B (zh) 一种tyk2抑制剂化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250818

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260421